摘要
目的研究依那普利联合前列地尔治疗糖尿病肾病的临床疗效。方法择取2018年2月—2019年3月于该院收治的62例糖尿病肾病患者作为研究对象,将其随机划分为分析组与常规组,各31例。分析组患者应用依那普利联合前列地尔治疗方案,常规组患者应用依那普利治疗,研究比较两组患者临床疗效。结果分析组患者接受治疗后各项临床指标(尿素氮、血清肌酐、尿酸、24 h尿蛋白以及尿蛋白排泄率)均优于常规组患者,两组间差异有统计学意义(P<0.05);分析组患者临床治疗有效率高于常规组,双方差异有统计学意义(P<0.05);分析组患者不良反应发生率略低于常规组患者,组间差异无统计学意义(P>0.05)。结论依那普利联合前列地尔用药治疗方案用于治疗糖尿病肾病临床疗效较好。
Objective To study the clinical efficacy of enalapril combined with alprostadil in the treatment of diabetic nephropathy.Methods Sixty-two patients with diabetic nephropathy admitted to the hospital from February 2018 to March 2019 were selected as the research subjects,and they were randomly divided into analysis group and routine group,with 31 cases each.Patients in the analysis group were treated with enalapril combined with alprostadil,and patients in the conventional group were treated with enalapril.The clinical efficacy of the two groups was compared.Results The clinical indicators(urea nitrogen,serum creatinine,uric acid,24-hour urinary protein,and urinary protein excretion rate)of patients in the analysis group after treatment were better than those in the conventional group);the effective rate of clinical treatment was higher in the analysis group than in the conventional group,and the difference was statistically significant(P<0.05);the incidence of adverse reactions in the analysis group was slightly lower than that in the conventional group,and the difference between the groups was not statistically significant(P>0.05).Conclusion Enalapril combined with alprostadil is a good treatment for diabetic nephropathy.
作者
丁海霞
刘怡
徐涛
宋梅
DING Hai-xia;LIU Yi;XU Tao;SONG Mei(Gaoxing Hospital of Lanshan District,Rizhao,Shandong Province,276811 China)
出处
《糖尿病新世界》
2020年第8期1-2,5,共3页
Diabetes New World Magazine
关键词
糖尿病肾病
依那普利
前列地尔
临床疗效
Diabetic nephropathy
Enalapril
Alprostadil
Clinical efficacy
